Akt/Protein
Kinase B (PKB) Inhibitors - Pipeline Analysis, Clinical Trials & Results,
Patents, Designations, Collaborations, and Other Developments published by
Pharma Proff Akt/PKB inhibitors therapeutics currently exhibits a proliferating
pipeline with 23 therapeutic candidates.
Akt plays a
critical role in the regulation of cell’s apoptotic pathway and it is being
studied extensively for targeting cancerous cells. Akt inhibitors are
therapeutics that obstruct the Akt pathways or Akt enzyme, which play a key
role in proliferation of solid tumors or cancer cells. Akt are composed of
various AGC kinases present in the cells that have hydrophobic motif at the
c-terminus of their catalytic core.
According to
the research findings, majority of the drug candidates in the pipeline are
being developed to be administered by the oral route. It has been observed that
oral route of medications is convenient; available in delayed or rapid release formulation;
provides improved patient’s compliance; less risk of systemic infections; and
has inexpensive nature. Akt inhibitors through oral route of administration
have shown positive results in the clinical studies.
Browse
Detailed Report on “Akt/Protein Kinase B (PKB) Inhibitors - Pipeline Analysis
2018, Clinical Trials & Results, Patents, Designations, Collaborations, and
Other Developments” at:
www.pharmaproff.com/report/pkb-inhibitors-pipeline-analysis
The
companies who are developing Akt/PKB inhibitors for the treatment of various
chronic diseases have shown positive clinical results in the various phases of
drug development. For instance, in June 2018, F. Hoffman-La Roche Ltd.
announced the interim results of Phase II study (LOTUS) for the drug candidate,
ipatasertib, that showed improvement in patients with triple negative breast
cancer (TNBC) toward overall survival (OS). This result was presented in the
2018 ASCO Annual Meeting, held in the U.S. The Phase II LOTUS study showed an
increase in OS up to 23.1 months (median) in interventional study, as compared
to 18.4 months (median) in placebo study.
Some of the
key players involved in the development of Akt/PKB inhibitors include F.
Hoffman-La-Roche Ltd, Eli Lilly & Company, Merck & Co. Inc., Novartis
AG, Denovo Biopharma LLC, Diffusion Pharmaceuticals Inc., Astex
Pharmaceuticals, ArQule Inc., Cotinga Pharmaceuticals Inc., and Oneness Biotech
Co. Ltd.
No comments:
Post a Comment